Mon, Jul 13 · 10:00

Overcome the translational challenges limiting the development of the next generation of CKD therapeutics. For the 3rd year, the Chronic Kidney Disease Drug Development Summit (CKD3) is putting the hottest topics in CKD drug development under the spotlight. Addressing questions including: what are the mechanisms driving the beneficial effects in SGLT2 inhibition, how is pharma harnessing the power of AI and what kidney organoids are providing innovation to target identification: CKD3 is the definitive, intimately focused forum promoting cross stakeholder discussion and networking to accelerate the next line of CKD drugs. Built with insight from 30+ kidney heavy weights including Reata Pharmaceuticals, AstraZeneca, Goldfinch Bio and Boehringer Ingelheim, the 3rd CKD3 Summit will comprehensively analyze the challenges in CKD drug development from genetics to costing, providing the thought-leading synthesis of all the information you need to accelerate meaningful therapeutics to renal disease patients.

URL:
Brochure: https://go.evvnt.com/613460-3?pid=5731

Prices:
Conference + 1 Workshop - Industry Pricing : USD 3929.0,
Conference only - Industry Pricing : USD 3099.0,
Workshop only - Industry Pricing : USD 930.0,
Conference + 1 Workshop - Biotech And Academic Pricing : USD 2399.0,
Conference only - Biotech And Academic Pricing : USD 1999.0,
Workshop only - Biotech And Academic Pricing : USD 600.0

Speakers: Andrew King, Head of Renal Discovery And Translational Medicine, Chinook Therapeutics, Anna Sundgren, Global Development Leader Lokelma And Bydureon, AstraZeneca, Annadoir Staveley, Associate Director of Clinical Disclosure And Data Sharing, Ethics And Compliance Otsuka Pharmaceuticals, Beno Freedman, Assistant Professor, Nephrology, University of Washington, Bruce Culleton, Vice President, Chief Medical Officer And Kidney Care, CVS Health , Dorothee Oberdhan, Associate Director, Health Outcomes, Otsuka Pharmaceuticals, Frank Czerwiec, Chief Medical Officer, Goldfinch Bio, Fredrik Erlandsson, Global Clinical Lead for Verinurad, AstraZeneca , Harry Alcorn, Chief Medical Officer, Diamedica, Heather Ascani, Director, Business Operations And Applied Systems Biology, University of Michigan, Hitesh Soni, Renal Fibrosis Gene Therapy Lead Renascent, Biosciences, Jean-Francois Thibodeau, Research Scientist II, Liminal BioSciences, Jeremy Duffield, Global Head of Human Biology, Vertex Pharmaceuticals, John Davis, Chief Executive Officer, KDIGO , Jonathan Himmelfarb, Director of the Kidney Research Institute And Professor of Medicine, University of Washington, Joseph Stavas, Senior Vice President, Clinical Development, inRegen, Josh Tarnoff, Chief Executive Officer, NephCure , Jyothis George, Global Head of Diabetes Clinical Development, Boehringer Ingelheim, Kevin Fowler, President, The Voice of the Patient, Lauren Lee, Chief Research Officer, NephCure, Liron Walsh, Vice President of Translational And Clinical Nephrology, Goldfinch Bio, Matt Breyer, Distinguished Scientist, Janssen, Matt Devalaraja, Executive Vice President, Head of Research And Development, Corvidia Therapeutics, Matthias Kretzler, Professor of Medicine Nephrology/ Internal Medicine And Bioinformatics, University of Michigan, Nick LaBella, Chief Scientific Officer, ZyVersa Therapeutics, Pernille Hansen, Senior Director And Head of Bioscience, AstraZeneca, Radko Komers, Director, Nephrology Retrophin, Ravi Kumar, Senior Vice President And Chief Scientific Officer, Acceleron Pharma, Robert Keane, Professor, Departments of Physiology, Biophysics And Neurological Surgery, University of Miami, Romer Gonzalez-Villalobos, Associate Director CKD/ NASH, Cardiovascular And Metabolism, Janssen Pharmaceuticals, Ron Perrone, Scientific Director, Clinical And Translational Research Center; Professor Tufts, University School of Medicine, Scott MacDonnell, Associate Director, Cardiovascular And Fibrosis Research, Regeneron Pharmaceuticals, Tzu-Ling (Karen) Tseng, Chief Executive Officer, Bio Preventive Medicine Corp, Uptal Patel, Executive Director, Clinical Research, Gilead, Vishal Vaidya, Translational Omics Group Head, Pfizer, Wenjun Ju, Associate Research Scientist of Internal Medicine, University of Michigan